Research programme: Parkinson's disease therapeutics - Denali Therapeutics
Alternative Names: OTV:SNCALatest Information Update: 25 Mar 2024
At a glance
- Originator Denali Therapeutics Inc
- Class Antiparkinsonians; Antisense oligonucleotides
- Mechanism of Action Alpha-synuclein expression inhibitors; Gene silencing
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Parkinson's disease